Kader Avan, Brangsch Julia, Kaufmann Jan O, Zhao Jing, Mangarova Dilyana B, Moeckel Jana, Adams Lisa C, Sack Ingolf, Taupitz Matthias, Hamm Bernd, Makowski Marcus R
Department of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany.
Department of Biology, Chemistry and Pharmacy, Institute of Biology, Freie Universität Berlin, Königin-Luise-Str. 1-3, 14195 Berlin, Germany.
Biomedicines. 2020 Dec 22;9(1):1. doi: 10.3390/biomedicines9010001.
This review summarizes recent developments regarding molecular imaging markers for magnetic resonance imaging (MRI) of prostate cancer (PCa). Currently, the clinical standard includes MR imaging using unspecific gadolinium-based contrast agents. Specific molecular probes for the diagnosis of PCa could improve the molecular characterization of the tumor in a non-invasive examination. Furthermore, molecular probes could enable targeted therapies to suppress tumor growth or reduce the tumor size.
本综述总结了前列腺癌(PCa)磁共振成像(MRI)分子成像标记物的最新进展。目前,临床标准包括使用非特异性钆基造影剂的磁共振成像。用于PCa诊断的特异性分子探针可以在非侵入性检查中改善肿瘤的分子特征。此外,分子探针可以实现靶向治疗,以抑制肿瘤生长或减小肿瘤大小。